WellSpring's prescription drugs and OTC brands have widespread distribution through pharmaceutical distributors, wholesalers, and major food and drug retailers. WellSpring prides itself on providing highly effective prescription medications in much-needed applications for niche patient groups. WellSpring also manufactures pharmaceuticals for other drug companies on a contract basis from its production facility in Ontario, Canada.
"WellSpring is Ancor's fifteenth acquisition of a healthcare company and combines our experience in pharmaceutical sales, OTC products, and contract manufacturing," said J. Randall Keene, managing partner at Ancor Capital Partners, who will serve as CEO of WellSpring. "We are very pleased to have teamed with Sentinel on this acquisition and we look forward to working closely with them," added Mr. Keene.